We are pleased to offer an extensive range of biomarker assays to support pharmacodynamic requirements.
This might be a protein marker, RNA markers, transcriptional analysis (individual or RNA seq by NGS) or small molecules.
We are always pleased to help with biomarker choice and literature evaluation – many biomarkers are of great experimental value but far from validated for use in the clinic – please see our pages on reference ranges and validation for comments which we hope you will find useful.
If the biomarker you require is not listed below, please let us know your requirements.
Please be aware that several of the genes coding for these bio-markers have significant population dependent polymorphisms. This is rarely taken into account in small scale (Phase I and Phase II) trials, but this can have a significant effect on biomarker data. We can offer genotyping assays for these polymorphisms and urge you to discuss this with us as part of your PD requirement.
Argininosuccinate lyase (ASL)
Blood Urea Nitrogen
C Reactive Protein
Carbohydrate Lipid Parameters (LDL, VLDL)
Carbohydrate Deficient Transferrin
Cystatin C Serum
Diagnostic Panel (12) ALP, ALT, AST, TB, GLU, BUN
Electrolyte Assays – Na, K, Cl, Ca, PHOS, Mg, tCO2
FLC Kappa Urine
FLC Lambda Urine
Hepatocyte Growth Factor
Ig/Light Chain, type kappa
Ig/Light Chain, type kappa urine 4
Ig/Light Chain, type lambda
Ig/Light Chain, type lambda urine 4
Interleukins, e.g. IL6, IL8
Liver Panel (7) ALP, ALT, AST, TP, ALB, TBIL, AMY, GLOB, A/G, B/C
MMPs / TIMPs
Plasminogen activator inhibitor -1
Preanaesthetic Panel (7) – ALP, ALT, TP, ALB, GLU, BUN, CREA, GLOB, A/G, B/C
Rheumatoid Factor (RF)
Tau (including phospho Tau)
Transferrin (for %CDT calculation)
Tumour Necrosis Factor Alpha
α2-Macroglobulin urine 4
We have facilities expertise for method development and validation if you need new asays or want to save money on bought in consumables such as new ELISA based procedures – antibody levels in blood, for example.